CANTON, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced
the election of John A. Fallon, M.D. to the Board of Directors.
"John’s broad-based payer, managed care and physician group practice management experience will be of great value to Collegium
as we launch our first commercial product, Xtampza® ER," said Michael Heffernan, CEO of Collegium. "His experience will
provide helpful perspective as we transition to a commercial stage company. We are very pleased to have him join the Collegium
team."
“Xtampza ER has the potential to offer a truly differentiated treatment option for patients with chronic pain,” said Dr. Fallon.
“I’m excited to join Collegium and look forward to working with the management team and board during this exciting time.”
Dr. Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts
("BCBS") from 2004 through 2015. Prior to his role at BCBS, Dr. Fallon served as Chief Executive Officer for clinical affairs
at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty
practice plan. His professional experience also includes the Partners Healthcare System, where he was Chairman of the physician
network. Dr. Fallon was also the CEO of Charter Professional Services Corporation and the founder and CEO of North Shore
Health System, a large physician-hospital organization in Massachusetts. He serves as the lead independent director on the board of
directors of Insulet Corporation (NASDAQ:PODD), a medical devices company, and as a member of the boards of directors of Exact
Sciences Corporation (NASDAQ:EXAS), a molecular diagnostics company and AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a specialty
pharmaceutical company. Dr. Fallon is Chairman of the board of directors of NEHI (Network for Excellence in Health
Innovation). In the past, he also served as a member of several not-for-profit boards, including: Alliance for Healthcare
Improvement, Massachusetts Health Quality Partners, Massachusetts E-Health Collaborative and Neighborhood Health Plan. He also
co-chaired, with the Massachusetts Secretary of Health and Human Services, the Massachusetts Patient Centered Medical Home
Initiative. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City
Hospital, and is Board Certified in Internal Medicine. He received a BA from the College of the Holy Cross, an MBA from the
University of South Florida and a Doctor of Medicine from Tufts University School of Medicine.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is
designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks
and uncertainties that may cause actual events or results to differ materially from the company's current expectations.
Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and
uncertainties relating to a number of other factors, including the following: our ability to commercialize our products and product
candidates; the existence of any patent infringement or similar litigation relating to any of our products or product candidates,
and costs and delays associated with such litigation; the size and growth potential of the markets for our product and product
candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or
with potential future collaborators; the rate and degree of market acceptance of our product and product candidates; the success,
cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or
become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property
protection for our product candidates. These and other risks are described under the heading "Risk Factors" in our Annual Report on
Form 10-K for the year ended December 31, 2015, and those risks described from time to time in other reports which we file with the
SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume
no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after
the date of this press release.
Contact: Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com
